Roche's Hemlibra Receives FDA's Breakthrough Therapy Designation for Hemophilia A without Factor VIII Inhibitors
Shots:
- The FDA’s BT designation is based on P-III HAVEN 3 study assessing Hemlibra vs no prophylaxis in 152 patients in ratio (2:2:1) with hemophilia A + prior treated with factor VIII therapy aged>12years
- The P-III HAVEN 3 study results: reduction in treated bleeds; superior to prior factor VIII prophylaxis; no thrombotic microangiopathy; no new safety signals observed
- Hemlibra (emicizumab) IV is a bispecific factor IXa- and factor X-directed Ab- with recommended dose qw- q2w- developed by Chugai and co-developed by Roche and Genentech. In 2017- Hemlibra received the US FDA approval to treat hemophilia A with factor VIII inhibitors in adults and children
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com